Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.

Allingham, Michael J; Mettu, Priyatham S; Cousins, Scott W.

Afiliação

Allingham MJ; Duke Center for Macular Diseases, Department of Ophthalmology, Duke Eye Center, Duke University School of Medicine, Durham, North Carolina.
Mettu PS; Duke Center for Macular Diseases, Department of Ophthalmology, Duke Eye Center, Duke University School of Medicine, Durham, North Carolina.
Cousins SW; Duke Center for Macular Diseases, Department of Ophthalmology, Duke Eye Center, Duke University School of Medicine, Durham, North Carolina.

Ophthalmol Sci ; 2(1): 100095, 2022 Mar.

Article em En | MEDLINE | ID: mdl-36246187

Palavras-chave

AE, adverse event; AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; DC, drusen complex; Dry age-related macular degeneration; Elamipretide; FAF, fundus autofluorescence; GA, geographic atrophy; HRD, high-risk drusen; LLQ, low-luminance questionnaire; LLRA, low-luminance binocular reading acuity; LLVA, low-luminance best-corrected visual acuity; Mitochondrial dysfunction; NCGA, noncentral, fovea-sparing geographic atrophy; NLRA, normal-luminance binocular reading acuity; Phase 1 clinical trial; RPE, retinal pigment epithelium; Retina; SD, standard deviation; logMAR, logarithm of the minimum angle of resolution

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article